Innovent, Chipscreen Biosciences to evaluate combination therapy in colorectal cancer patients

This article was originally published here

Under the collaboration, the firms will evaluate the safety and tolerability of the combination therapy of Innovent’s Tyvyt (generic name: sintilimab injection), a fully human anti-programmed cell death

The post Innovent, Chipscreen Biosciences to evaluate combination therapy in colorectal cancer patients appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply